Emodin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Anti-Inflammatory and Anti-Oxidative Activities in Rats
- PMID: 29290631
- PMCID: PMC5759514
- DOI: 10.12659/msm.905496
Emodin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Anti-Inflammatory and Anti-Oxidative Activities in Rats
Abstract
BACKGROUND Idiopathic pulmonary fibrosis (IPF) can severely damage lung function, which may result in death. Emodin is a major ingredient of rhubarb and has been proven to protect against lung disruptions. Our study focused on the potential medicinal effect of emodin against IPF. MATERIAL AND METHODS The experiment subjects were fully-grown male Sprague-Dawley rats with average weight of 180-220 kg. Histological analyses, Western blotting analysis, quantitative real-time PCR, and statistical analysis were used in the study. RESULTS We found that emodin significantly reduced lung structural distortion, collagen overproduction, massive inflammatory cells infiltration, proinflammatory cytokines expansion, and injuries caused by administration of bleomycin (BLM). Additionally, emodin suppressed the accumulation of p-IκBα and NF-κB, while stimulating the Nrf2-antioxidant signaling process in damaged lungs. Emodin inhibited epithelial-mesenchymal transition (EMT) induced by BLM in the lungs. Moreover, emodin suppressed the TGF-β1 expression and the downstream signal molecules p-Smad-2 and p-Smad-3, which are reinforced by BLM. Emodin can also reverse EMT-like shifts induced by recombinant TGF-β1 in alveolar epithelial cultured cells. CONCLUSIONS The effect of emodin in fibrotic lung injury is closely related to its favorable properties of anti-inflammation and anti-oxidation.
Conflict of interest statement
None.
Figures
Similar articles
-
Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-κB and TGF-β1/Smad-2/-3 pathways.Cell Stress Chaperones. 2016 Mar;21(2):239-49. doi: 10.1007/s12192-015-0654-4. Epub 2015 Nov 17. Cell Stress Chaperones. 2016. PMID: 26577463 Free PMC article.
-
Emodin alleviates bleomycin-induced pulmonary fibrosis in rats.Toxicol Lett. 2016 Nov 16;262:161-172. doi: 10.1016/j.toxlet.2016.10.004. Epub 2016 Oct 4. Toxicol Lett. 2016. PMID: 27717887
-
Emodin ameliorates bleomycin-induced pulmonary fibrosis in rats by suppressing epithelial-mesenchymal transition and fibroblast activation.Sci Rep. 2016 Oct 24;6:35696. doi: 10.1038/srep35696. Sci Rep. 2016. PMID: 27774992 Free PMC article.
-
Immune Mechanisms of Pulmonary Fibrosis with Bleomycin.Int J Mol Sci. 2023 Feb 5;24(4):3149. doi: 10.3390/ijms24043149. Int J Mol Sci. 2023. PMID: 36834561 Free PMC article. Review.
-
The role of natural products in the prevention and treatment of pulmonary fibrosis: a review.Food Funct. 2021 Feb 15;12(3):990-1007. doi: 10.1039/d0fo03001e. Food Funct. 2021. PMID: 33459740 Review.
Cited by
-
The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9.Heliyon. 2023 Aug 29;9(9):e19371. doi: 10.1016/j.heliyon.2023.e19371. eCollection 2023 Sep. Heliyon. 2023. PMID: 37809924 Free PMC article. Review.
-
A systematic review of the research progress of traditional Chinese medicine against pulmonary fibrosis: from a pharmacological perspective.Chin Med. 2023 Aug 3;18(1):96. doi: 10.1186/s13020-023-00797-7. Chin Med. 2023. PMID: 37537605 Free PMC article. Review.
-
Dietary emodin alleviates lipopolysaccharide-induced intestinal mucosal barrier injury by regulating gut microbiota in piglets.Anim Nutr. 2023 May 16;14:152-162. doi: 10.1016/j.aninu.2023.05.004. eCollection 2023 Sep. Anim Nutr. 2023. PMID: 37455790 Free PMC article.
-
Searching for Novel Candidate Small Molecules for Ameliorating Idiopathic Pulmonary Fibrosis: a Narrative Review.Biomol Ther (Seoul). 2023 Sep 1;31(5):484-495. doi: 10.4062/biomolther.2023.056. Epub 2023 May 31. Biomol Ther (Seoul). 2023. PMID: 37254717 Free PMC article. Review.
-
From Basic Research to Clinical Practice: Considerations for Treatment Drugs for Silicosis.Int J Mol Sci. 2023 May 5;24(9):8333. doi: 10.3390/ijms24098333. Int J Mol Sci. 2023. PMID: 37176040 Free PMC article. Review.
References
-
- Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: A review. Respirology. 2016;21:245–58. - PubMed
-
- Spagnolo P, Maher TM, Richeldi L. Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. Pharmacol Ther. 2015;152:18–27. - PubMed
-
- Chakraborty S, Chopra P, Ambi SV, et al. Emerging therapeutic interventions for idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2014;23:893–910. - PubMed
-
- King TE, Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
